×
Repeat LTBI testing best in patients taking biologics with new risk factors
https://www.mdedge.com/fedprac/article/213923/rheumatoid-arthritis/repeat-ltbi-testing-best-patients-taking-biologics-new?channel=234
Jeff Craven

Dec 9th, 2019 - ATLANTA – Patients taking biologics who received latent tuberculosis testing on an annual basis were unlikely to convert from a negative QuantiFERON test to a positive result, which suggests that the test may be unnecessary for patients without new tuberculosis risk factors, according to research presented at the annual meeting of the American College of Rheumatology. In addition, nearly all of.

Perioperative antirheumatic drug use does not impact postsurgery infection rate in RA patients
https://www.mdedge.com/jcomjournal/article/213883/rheumatoid-arthritis/perioperative-antirheumatic-drug-use-does-not-impact?channel=302
Jeff Craven

Dec 9th, 2019 - ATLANTA – Patients with rheumatoid arthritis were more at risk of postoperative infection because of a high Charlson Comorbidity Index or longer surgery time than because of perioperative use of antirheumatic medications, according to a presentation at the annual meeting of the American College of Rheumatology. Jeff Craven/MDedge News Dr.

Updated gout guidelines: Don’t let kidney function dictate allopurinol dosing
https://www.mdedge.com/clinicianreviews/article/213863/gout/updated-gout-guidelines-dont-let-kidney-function-dictate?channel=53
M. Alexander Otto

Dec 9th, 2019 - ATLANTA – Soon-to-be-published gout guidelines from the American College of Rheumatology will recommend dosing allopurinol above 300 mg/day to get serum urate below 6 mg/dL, even in people with renal impairment. M.

Evidence grows for early axSpA treatment, uveitis flare prevention
https://www.mdedge.com/rheumatology/article/213740/ankylosing-spondylitis/evidence-grows-early-axspa-treatment-uveitis?channel=299
Denis Poddubnyy, MD

Dec 6th, 2019 - The findings from the C-axSpAnd study that Jonathan Kay, MD, and colleagues reported at the annual meeting of the American College of Rheumatology are not surprising. Earlier studies in patients with ankylosing spondylitis showed that short symptom duration is one of the best predictors of good treatment response to TNFi therapy.

Upadacitinib doubles ASAS 40 response vs. placebo in ankylosing spondylitis
https://www.mdedge.com/internalmedicine/article/213422/ankylosing-spondylitis/upadacitinib-doubles-asas-40-response-vs?channel=53
Sharon Worcester

Dec 3rd, 2019 - ATLANTA – Upadacitinib (Rinvoq), a selective Janus kinase 1 (JAK1) inhibitor, significantly improved the signs and symptoms of active ankylosing spondylitis, compared with placebo, in the randomized, placebo-controlled, phase 2/3 SELECT-AXIS 1 study. Dr.

Tanezumab posts higher safety event rate than NSAIDs over 1 year in hip, knee OA
https://www.mdedge.com/rheumatology/article/213000/osteoarthritis/tanezumab-posts-higher-safety-event-rate-nsaids-over-1?channel=53
Jeff Craven

Nov 25th, 2019 - ATLANTA – Patients with moderate to severe osteoarthritis of the hip and knee who took the investigational anti-nerve growth factor monoclonal antibody tanezumab experienced a significantly higher rate of joint safety events than that of patients who received NSAIDs as part of a recent randomized, double-blind, active-controlled, phase 3 study. Jeff Craven/MDedge News Dr.

Large population-based study underscores link between gout, CVD event risk
https://www.mdedge.com/cardiology/article/212979/gout/large-population-based-study-underscores-link-between-gout-cvd-event?channel=39313
Sharon Worcester

Nov 23rd, 2019 - ATLANTA – Gout is associated with an increased risk of both fatal and nonfatal cardiovascular disease events, according to a large population-based health data linkage study in New Zealand. Sharon Worcester/MDedge News Dr.

SPIRIT-H2H results confirm superiority of ixekizumab over adalimumab for PsA
https://www.mdedge.com/rheumatology/psoriatic-arthritis-resource-center/article/212887/psoriatic-arthritis/spirit-h2h?channel=281
Sharon Worcester

Nov 21st, 2019 - ATLANTA – Ixekizumab (Taltz) provided significantly greater improvement in joint and skin symptoms, compared with adalimumab (Humira), in biologic-naive patients with active psoriatic arthritis (PsA), according to final 52-week safety and efficacy results from the randomized SPIRIT-H2H study. Dr.

COAST-X top-line results: Ixekizumab improves nonradiographic axSpA vs. placebo
https://www.mdedge.com/rheumatology/article/212841/ankylosing-spondylitis/coast-x-top-line-results-ixekizumab-improves?channel=53
Sharon Worcester

Nov 21st, 2019 - ATLANTA – Adding ixekizumab (Taltz) to conventional background medications significantly improved the signs and symptoms of nonradiographic axial spondyloarthritis (axSpA) in the randomized, double-blind, placebo-controlled phase 3 COAST-X trial. Sharon Worcester/MDedge News Dr.

Fewer people are dying from systemic sclerosis at younger ages
https://www.mdedge.com/internalmedicine/article/212836/lupus-connective-tissue-diseases/fewer-people-are-dying-systemic?channel=290
Jeff Craven

Nov 21st, 2019 - ATLANTA – Patients with systemic sclerosis aged 44 years and younger in the United States now have mortality comparable to that of the general population in that age group, according to recent results presented at the annual meeting of the American College of Rheumatology. Dr.

Rituximab tops azathioprine for relapsing ANCA-associated vasculitis remission maintenance
https://www.mdedge.com/internalmedicine/article/212794/lupus-connective-tissue-diseases/rituximab-tops-azathioprine?channel=290
M. Alexander Otto

Nov 21st, 2019 - ATLANTA – Rituximab (Rituxan) is superior to azathioprine (Imuran) for preventing ANCA-associated vasculitis relapses in patients with histories of previous relapses, according to a randomized trial of 170 patients presented at the annual meeting of the American College of Rheumatology. Dr.

Biologic DMARDs appear as effective in elderly-onset RA as in young-onset RA
https://www.mdedge.com/rheumatology/article/212492/rheumatoid-arthritis/biologic-dmards-appear-effective-elderly-onset-ra?channel=53
Sharon Worcester

Nov 18th, 2019 - ATLANTA – Elderly-onset and young-onset rheumatoid arthritis patients initiating treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) respond similarly with respect to clinical improvement at 48 weeks and adverse events, data from a large registry in Japan suggest. Sharon Worcester/MDedge News Dr.

PREVENT trial shows benefits of secukinumab for nonradiographic axSpA
https://www.mdedge.com/internalmedicine/article/212409/ankylosing-spondylitis/prevent-trial-shows-benefits-secukinumab?channel=39313
Jeff Craven

Nov 15th, 2019 - ATLANTA – Patients with nonradiographic axial spondyloarthritis who received secukinumab with or without loading doses showed improvements in physical function, quality of life, inflammation, and other disease signs and symptoms, according to results from a phase 3 study presented at the annual meeting of the American College of Rheumatology. Jeff Craven/MDedge News Dr.

Marked increase in psoriasis seen with TNFi use in pediatric inflammatory diseases
https://www.mdedge.com/rheumatology/article/212202/pediatrics/marked-increase-psoriasis-seen-tnfi-use-pediatric?channel=53
M. Alexander Otto

Nov 13th, 2019 - ATLANTA – Tumor necrosis factor inhibitors almost quadrupled the risk of psoriasis in children with inflammatory bowel disease, juvenile idiopathic arthritis, or chronic nonbacterial osteomyelitis in a review of 4,111 patients at the Children’s Hospital of Philadelphia. Dr.

Cost-effectiveness of Duloxetine for Knee OA Patients Whose Pain Can’t Be Controlled by NSAIDs
https://acrabstracts.org/abstract/cost-effectiveness-of-duloxetine-for-knee-oa-patients-whose-pain-cant-be-controlled-by-nsaids/
James Sullivan, Jeffrey Katz 2 and Elena Losina, Brigham and Women's Hospital et. al.

Nov 13th, 2019 - Background/Purpose: Knee OA is a disabling condition affecting over 14 million adults in the US. NSAIDs provide only short-term pain relief, creating the need for additional pain management. Growing evidence indicates that chronic knee OA pain is associated with centralized pain pathways. Based on these considerations, ACR and OARSI recommend or conditionally recommend the use of duloxetine. Th...

Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
https://acrabstracts.org/abstract/clinical-and-functional-outcomes-among-rheumatoid-arthritis-patients-switching-between-jak1-selective-inhibitor-upadacitinib-and-adalimumab-following-insufficient-response/
Roy Fleischmann, Mark Genovese, Ricardo Blanco et. al.

Nov 13th, 2019 - Background/Purpose: The goal of RA treatment is to achieve clinical remission or, at minimum, low disease activity (LDA). Modification of initial csDMARD therapy with the addition of a biologic (b) DMARD, such as a tumor necrosis factor inhibitor (TNFi), or Janus Kinase inhibitor (JAKi) may be needed following an inadequate response (IR).1 Switches in mechanism of action have been advocated in ...

Cannabis Use Among Patients in a Large US Rheumatic Disease Registry
https://acrabstracts.org/abstract/cannabis-use-among-patients-in-a-large-us-rheumatic-disease-registry/
Kristin Wipfler, Teresa Simon, Patricia Katz et. al.

Nov 13th, 2019 - Background/Purpose: Legalization of cannabis use is rapidly increasing worldwide, raising the need to evaluate trends and medical implications. A systematic literature review showed inconsistent results on tolerability and safety of cannabis-based medicines for any chronic pain [1]. Additionally, little is known about the use and effectiveness of cannabis in rheumatic diseases [2]. We sought to...

Baseline Clinical and Serological Findings in Pediatric-Onset Discoid Lupus Erythematosus: Analysis of a Multicenter Retrospective Cohort Study
https://acrabstracts.org/abstract/baseline-clinical-and-serological-findings-in-pediatric-onset-discoid-lupus-erythematosus-analysis-of-a-multicenter-retrospective-cohort-study/
Nnenna Ezeh, Kevin Buhr, Cordellia Nguyen et. al.

Nov 13th, 2019 - Background/Purpose: DLE is a rare, disfiguring disorder in children. Small retrospective studies suggest 20-25% of patients progress to SLE. Progression risk factors are poorly understood, but DLE has been associated with delay in SLE diagnosis and reduced access to care. This multicenter retrospective cohort study aimed to describe baseline characteristics and clinical phenotypes of pediatric ...

Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients
https://acrabstracts.org/abstract/model-based-cost-effectiveness-analyses-comparing-combinations-of-urate-lowering-therapy-and-anti-inflammatory-treatment-in-newly-diagnosed-gout-patients/
Celine van de Laar, Martijn A.H. Oude Voshaar, Carly Janssen et. al.

Nov 13th, 2019 - Background/Purpose: To assess the cost-effectiveness of various combinations of urate lowering therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout patients, from the Dutch societal perspective.  Methods: The Anakinra versus Treatment as usual in the Treatment of ACute Gout (ATTACG) study was the  primary data source for  this study.  Since only patients with ...

Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway
https://acrabstracts.org/abstract/machine-learning-classification-identifies-a-subset-of-patients-that-improve-on-abatacept-via-modulation-of-a-cd28-related-pathway/
Bhaven Mehta, Jennifer Franks, Yiwei Yuan et. al.

Nov 13th, 2019 - Background/Purpose: We analyzed a phase 2 study designed to assess the efficacy of abatacept in patients with diffuse Systemic Sclerosis (SSc). In this work, we analyze data from ASSET and seek to confirm the hypothesis that patients in the inflammatory subset on abatacept show a significant decline in modified Rodnan Skin Score (mRSS), which is correlated to modulation of pathways related to t...